Company Overview and News

20
Cannabis Sativa Inc. Makes Huge Losses On Little Revenue. What Is Going On Here?

2018-05-30 seekingalpha
If you are into the marijuana sector hype, it might be tempting to scoop up one of the smaller players exposed to different use cases for legal cannabis. The company has a portfolio of these, which I'll quickly present later. However, I strongly feel there are too many warning signs concerning Cannabis Sativa Inc. (OTCQB:CBDS) for a prudent investor to take a stake.
TWMJF ACB WEED ACBFF REFG CGC CBDS

1
CBDS / Cannabis Sativa, Inc. 10-Q/A (Quarterly Report)

2018-05-18 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q
CBDS

1
CBDS / Cannabis Sativa, Inc. 10-Q (Quarterly Report)

2018-05-15 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q
CBDS

1
ICC Labs Receives Organic Hemp Certification, Readies for Harvest and Continues Construction of Laboratory  

2018-05-11 globenewswire
VANCOUVER, British Columbia, May 11, 2018 (GLOBE NEWSWIRE) -- ICC Labs Inc. (“ICC Labs” or the “Company”) (TSX-V:ICC) (Frankfurt:2Q9) is pleased to announce that its wholly-owned subsidiary, Tersum S.A., obtained a 100% organic certificate for hemp (Cannabis Sativa) from the Organización Internacional Agropecuaria. The certification applies to hemp produced at the Company’s Canelones site in Uruguay, where the Company is authorized by the Ministry of Agriculture to grow hemp on up to 101 acres.
CBDS

1
CBDS / Cannabis Sativa, Inc. 10-K/A (Annual Report)

2018-04-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
CBDS

1
CBDS / Cannabis Sativa, Inc. 10-K (Annual Report)

2018-04-04 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 &nb
CBDS

1
CBDS / Cannabis Sativa, Inc. NT 10-K

2018-04-03 sec.gov
U UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b
CBDS

1
CBDS / Cannabis Sativa, Inc. null

2018-03-16 sec.gov
CANNABIS SATIVA, INC. 1646 W. Pioneer Blvd. Suite 120 Mesquite, NV 89027
CBDS

1
Relevium Announces Initial Launch of Hempco's PlanetHemp® in the USA

2018-03-13 marketwired
MONTREAL, QUEBEC--(Marketwired - March 13, 2018) - Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) ("Relevium") and Hempco Food and Fiber Inc (TSX VENTURE:HEMP) ('Hempco') are pleased to announce the launch of five PlanetHemp® products in the U.S., which are expected to be live the week of March 19, 2018.
RLV CBDS

CBDS : Cannabis Sativa Stock Analysis and Research Report

2017-11-16 - Asif

Cannabis Sativa was incorporated under the laws of Nevada in November 2005. The company acquired a wholly-owned subsidiary named Kush, a Nevada corporation, in June 2014 in exchange for shares of its common stock. Since November 2015, Kush has been spun off and is no longer a subsidiary of the Company. The company's wholly-owned subsidiary Wild Earth Naturals, Inc. ("Wild Earth") was acquired by it in July 2013 in exchange for shares of its common stock. The company acquired a 50.1% interest in its subsidiary iBudtender, Inc., including its wholly owned subsidiary iBudtender, LLC, a California limited liability company (collectively, “iBudtender”) in August of 2016 in exchange for cash and shares of its common stock. On July 27, 2017, the company acquired a 51% interest in PrestoCorp, a Delaware corporation, in exchange for shares of its common stock. From its inception through September 30, 2013, the company were engaged in the tanning salon business and operated a tanning salon ...

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 13764T105